|
|
Article: Nastech Submits Investigational New Drug Application for PYY3-36 Nasal Spray to Treat Obesity.
- Article from:
- PR Newswire
- Article date:
- June 7, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BOTHELL, Wash., June 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for PYY3-36 (PYY) nasal spray, the company's lead investigational product candidate for treatment of obesity. The filing of the IND precedes the initiation of clinical studies in the United States.
The study included in the IND is designed to evaluate the pharmacokinetic parameters, appetite, food intake and safety of various dosing regimens of PYY nasal spray in obese subjects. The objective of study is to determine the optimal dosing regimens that will be ...